质子泵抑制剂和腹膜透析相关性腹膜炎:澳大利亚纽卡斯尔的一项队列研究。

IF 1.5 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Kate Richards, Eswari Vilayur
{"title":"质子泵抑制剂和腹膜透析相关性腹膜炎:澳大利亚纽卡斯尔的一项队列研究。","authors":"Kate Richards, Eswari Vilayur","doi":"10.1111/imj.70128","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peritoneal dialysis (PD)-associated peritonitis results in poor outcomes, including hospitalisation, PD discontinuation and death. Proton pump inhibitors (PPIs) have been linked to an increased risk of organism-specific and/or overall peritonitis in prior studies, yet they are commonly prescribed in the dialysis population.</p><p><strong>Aims: </strong>To evaluate whether PPIs are associated with an increased risk of overall peritonitis in a local cohort.</p><p><strong>Methods: </strong>We retrospectively identified patients with incident PD at a single Australian centre between 2012 and 2021. Baseline comorbidities, medications and PD outcomes were recorded. Patients were stratified by PPI exposure. We assessed whether PPI use affected time to first peritonitis using multivariate Cox proportional hazard modelling. The overall rate of peritonitis per patient-year was compared between groups.</p><p><strong>Results: </strong>Of 219 patients, 94 were exposed to PPIs, of whom 40 of 94 (42.6%) developed peritonitis, compared to 56 of 125 (44.8%) of the unexposed group. PPI use was not associated with time to first peritonitis in a multivariate Cox analysis (hazard ratio 0.78 (95% confidence interval 0.51-1.18), P = 0.2). The peritonitis rate was marginally lower in the PPI group. Atherosclerotic vascular disease was associated with peritonitis in an exploratory analysis.</p><p><strong>Conclusions: </strong>PPI use was not associated with peritonitis risk in this cohort. Further work is needed to explain the discrepant findings between studies to date, including whether PPIs modulate the risk of peritonitis caused by specific organisms.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proton pump inhibitors and peritoneal dialysis-associated peritonitis: a cohort study in Newcastle, Australia.\",\"authors\":\"Kate Richards, Eswari Vilayur\",\"doi\":\"10.1111/imj.70128\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Peritoneal dialysis (PD)-associated peritonitis results in poor outcomes, including hospitalisation, PD discontinuation and death. Proton pump inhibitors (PPIs) have been linked to an increased risk of organism-specific and/or overall peritonitis in prior studies, yet they are commonly prescribed in the dialysis population.</p><p><strong>Aims: </strong>To evaluate whether PPIs are associated with an increased risk of overall peritonitis in a local cohort.</p><p><strong>Methods: </strong>We retrospectively identified patients with incident PD at a single Australian centre between 2012 and 2021. Baseline comorbidities, medications and PD outcomes were recorded. Patients were stratified by PPI exposure. We assessed whether PPI use affected time to first peritonitis using multivariate Cox proportional hazard modelling. The overall rate of peritonitis per patient-year was compared between groups.</p><p><strong>Results: </strong>Of 219 patients, 94 were exposed to PPIs, of whom 40 of 94 (42.6%) developed peritonitis, compared to 56 of 125 (44.8%) of the unexposed group. PPI use was not associated with time to first peritonitis in a multivariate Cox analysis (hazard ratio 0.78 (95% confidence interval 0.51-1.18), P = 0.2). The peritonitis rate was marginally lower in the PPI group. Atherosclerotic vascular disease was associated with peritonitis in an exploratory analysis.</p><p><strong>Conclusions: </strong>PPI use was not associated with peritonitis risk in this cohort. Further work is needed to explain the discrepant findings between studies to date, including whether PPIs modulate the risk of peritonitis caused by specific organisms.</p>\",\"PeriodicalId\":13625,\"journal\":{\"name\":\"Internal Medicine Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/imj.70128\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:腹膜透析(PD)相关性腹膜炎导致不良结果,包括住院、PD停药和死亡。在先前的研究中,质子泵抑制剂(PPIs)与生物体特异性和/或全局性腹膜炎的风险增加有关,但它们通常在透析人群中使用。目的:评估PPIs是否与局部队列中整体腹膜炎风险增加相关。方法:我们回顾性地确定了2012年至2021年在澳大利亚一个中心发生的PD患者。记录基线合并症、药物治疗和PD结果。根据PPI暴露对患者进行分层。我们使用多变量Cox比例风险模型评估PPI使用是否影响首次腹膜炎发生的时间。比较两组患者每年腹膜炎的总发生率。结果:219例患者中,94例暴露于PPIs,其中94例中有40例(42.6%)发生腹膜炎,而未暴露组的125例中有56例(44.8%)发生腹膜炎。多变量Cox分析显示,PPI使用与首次腹膜炎发生时间无关(风险比0.78(95%可信区间0.51-1.18),P = 0.2)。PPI组腹膜炎发生率略低。一项探索性分析表明,动脉粥样硬化性血管疾病与腹膜炎相关。结论:在该队列中,PPI的使用与腹膜炎风险无关。需要进一步的工作来解释迄今为止研究之间的差异发现,包括PPIs是否调节由特定生物体引起的腹膜炎的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Proton pump inhibitors and peritoneal dialysis-associated peritonitis: a cohort study in Newcastle, Australia.

Background: Peritoneal dialysis (PD)-associated peritonitis results in poor outcomes, including hospitalisation, PD discontinuation and death. Proton pump inhibitors (PPIs) have been linked to an increased risk of organism-specific and/or overall peritonitis in prior studies, yet they are commonly prescribed in the dialysis population.

Aims: To evaluate whether PPIs are associated with an increased risk of overall peritonitis in a local cohort.

Methods: We retrospectively identified patients with incident PD at a single Australian centre between 2012 and 2021. Baseline comorbidities, medications and PD outcomes were recorded. Patients were stratified by PPI exposure. We assessed whether PPI use affected time to first peritonitis using multivariate Cox proportional hazard modelling. The overall rate of peritonitis per patient-year was compared between groups.

Results: Of 219 patients, 94 were exposed to PPIs, of whom 40 of 94 (42.6%) developed peritonitis, compared to 56 of 125 (44.8%) of the unexposed group. PPI use was not associated with time to first peritonitis in a multivariate Cox analysis (hazard ratio 0.78 (95% confidence interval 0.51-1.18), P = 0.2). The peritonitis rate was marginally lower in the PPI group. Atherosclerotic vascular disease was associated with peritonitis in an exploratory analysis.

Conclusions: PPI use was not associated with peritonitis risk in this cohort. Further work is needed to explain the discrepant findings between studies to date, including whether PPIs modulate the risk of peritonitis caused by specific organisms.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信